NEW YORK (360Dx) – Diagnostics and pharmaceuticals developer Opko Health reported after the close of the market on Wednesday that its fourth quarter revenues slipped by a fraction of 1 percent.

For the three months ended Dec. 31, 2016, the company posted $275.5 million in revenues, down from $276.2 million in the year-ago period and well short of the consensus Wall Street estimate of $310.8 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.